ACC2-Selective Composition for Fatty Liver Without Triglyceride Rise
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) lack an effective ACC2-selective inhibitor that does not cause side effects such as increased plasma triglycerides or decreased platelet counts, and existing ACC1/2 dual inhibitors have shown adverse effects in clinical trials.
Innovation Solution
A pharmaceutical composition comprising a compound with high ACC2-selective inhibitory action, represented by Formula (I), which avoids side effects like increased plasma triglycerides and decreased platelets, and is designed to treat and prevent NAFLD, NASH, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ACC1/2 dual inhibitors are used to treat NAFLD, then fatty liver disease is treated, but plasma triglycerides increase and platelet counts decrease
Solution Approach 1:
The invention segments the target enzyme inhibition by designing a compound that selectively inhibits ACC2 while sparing ACC1. This selectivity is achieved through specific molecular structure (Formula I) that fits the ACC2 active site but not ACC1, thereby treating NAFLD through ACC2 inhibition without the adverse effects caused by ACC1 inhibition such as decreased platelet counts and increased plasma triglycerides.
Solution Approach 2:
The compound in Formula I exhibits local quality by demonstrating differential inhibitory activity against ACC1 and ACC2 isoforms. The molecular structure is optimized to interact specifically with ACC2's active site, creating a localized effect that targets liver fat metabolism without affecting other physiological processes dependent on ACC1 activity, such as platelet production and plasma triglyceride regulation.
2Reliability
If existing ACC inhibitors are used, then liver fat accumulation is reduced, but adverse effects occur including increased plasma triglycerides and cardiovascular risk
Solution Approach 1:
The invention segments the ACC enzyme family into two distinct targets and selectively inhibits only ACC2. This is accomplished through the molecular design in Formula I, which contains specific structural features (R1 as haloalkyl or non-aromatic carbocyclyl, R2 as hydrogen or halogen, R3 as halogen, and specific ring A structure) that confer ACC2 selectivity. By avoiding ACC1 inhibition, the compound prevents adverse effects on plasma triglycerides and cardiovascular health while maintaining effectiveness in reducing liver fat accumulation.
Solution Approach 2:
The invention changes the selectivity parameter of ACC inhibition by designing a compound with specific physicochemical properties and molecular structure that preferentially bind to ACC2 over ACC1. The structural parameters in Formula I (haloalkyl or non-aromatic carbocyclyl at R1, halogen at R3, specific ring A configuration) are optimized to achieve this selectivity, thereby altering the pharmacological profile to eliminate adverse effects while preserving therapeutic benefit.
Data Source
AI summary
A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):whereinR1 is haloalkyl or non-aromatic carbocyclyl,R2 is a hydrogen atom or halogen,R3 is halogen,ring A is a group represented by the formula:-L1- is —O—(CH2)—, —(CH2)2—, or the like,R4 is alkyl or haloalkyl, andR5 is alkylcarbonyl or carbamoyl,or a pharmaceutically acceptable salt thereof.